KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
Kura Oncology (KURA) shares gained 37.6% over the past month, driven by strong commercial momentum for its lead product Komzifti (ziftomenib), which achieved $9.1 million in Q2 2026 revenues with 57% sequential growth. The company expects multiple data readouts in 2026 and has $519 million in cash to support pipeline execution, with potential expansion of ziftomenib into earlier AML treatment lines and darlifarnib development in solid tumors.